Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Davis

Showing results (241-250 of 437) with videos related to

Pageof 44
Sort By:
Current Rheumatology Reports|February 12, 2026
NOD2-Related Multisystem Inflammatory Disorders and Recent AdvancesDi Wu, Tomoko Matsuda, Danielle Xie, et al.
Seminars in Arthritis and Rheumatism|March 2, 2025
Quantifying and improving rheumatoid arthritis algorithm performance in biobank settingsVanessa L Kronzer, Katrina A Williamson, Andrew C Hanson, et al.
JAMA Neurology|May 19, 2020
Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System EventsAmy Kunchok, Allen J Aksamit, John M Davis, et al.
Clinical Rheumatology|July 3, 2019
Optimization of flare management in patients with rheumatoid arthritis: results of a randomized controlled trialElena Myasoedova, Cynthia S Crowson, Rachel E Giblon, et al.
Schizophrenia Research|May 12, 2010
Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month studyRobert C Smith, Jean-Pierre Lindenmayer, Qiaoyan Hu, et al.
Schizophrenia Research|December 4, 2012
Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind studyRobert C Smith, Hua Jin, Chunbo Li, et al.
Nature Communications|September 16, 2020
A predictive index for health status using species-level gut microbiome profilingVinod K Gupta, Minsuk Kim, Utpal Bakshi, et al.
Schizophrenia Bulletin|June 23, 2023
Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-TrialsDongfang Wang, Johannes Schneider-Thoma, Spyridon Siafis, et al.
The Journal of Rheumatology|April 17, 2008
Mortality trends in rheumatoid arthritis: the role of rheumatoid factorAngel Gonzalez, Murat Icen, Hilal Maradit Kremers, et al.
Schizophrenia Research|April 10, 2012
A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorderMark Weiser, Ari A Gershon, Katya Rubinstein, et al.
Pageof 44

Showing results (241-250 of 437) with videos related to

Sort By:
Pageof 44
Current Rheumatology Reports|February 12, 2026
NOD2-Related Multisystem Inflammatory Disorders and Recent AdvancesDi Wu, Tomoko Matsuda, Danielle Xie, et al.
Seminars in Arthritis and Rheumatism|March 2, 2025
Quantifying and improving rheumatoid arthritis algorithm performance in biobank settingsVanessa L Kronzer, Katrina A Williamson, Andrew C Hanson, et al.
JAMA Neurology|May 19, 2020
Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System EventsAmy Kunchok, Allen J Aksamit, John M Davis, et al.
Clinical Rheumatology|July 3, 2019
Optimization of flare management in patients with rheumatoid arthritis: results of a randomized controlled trialElena Myasoedova, Cynthia S Crowson, Rachel E Giblon, et al.
Schizophrenia Research|May 12, 2010
Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month studyRobert C Smith, Jean-Pierre Lindenmayer, Qiaoyan Hu, et al.
Schizophrenia Research|December 4, 2012
Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind studyRobert C Smith, Hua Jin, Chunbo Li, et al.
Nature Communications|September 16, 2020
A predictive index for health status using species-level gut microbiome profilingVinod K Gupta, Minsuk Kim, Utpal Bakshi, et al.
Schizophrenia Bulletin|June 23, 2023
Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-TrialsDongfang Wang, Johannes Schneider-Thoma, Spyridon Siafis, et al.
The Journal of Rheumatology|April 17, 2008
Mortality trends in rheumatoid arthritis: the role of rheumatoid factorAngel Gonzalez, Murat Icen, Hilal Maradit Kremers, et al.
Schizophrenia Research|April 10, 2012
A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorderMark Weiser, Ari A Gershon, Katya Rubinstein, et al.
Pageof 44